Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.31 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
| ▸ | DRD1 | P21728 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | ANPEP | P15144 | 2/20 | 0.30 |
| ▸ | DPP4 | P27487 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15993784 | 0.90 | ACHE (0.40) | ALOX15ACHEMEN1RAB9AKMT2A | |
| SCHEMBL15993914 | 0.89 | ACHE (0.42) | ALOX15ACHEMEN1RAB9AKMT2A | |
| SCHEMBL15993923 | 0.86 | ACHE (0.41) | ACHEMEN1RAB9AKMT2ADRD1 | |
| SCHEMBL17602033 | 0.84 | ALOX15 (0.36) | ALOX15ACHE | |
| SCHEMBL17602007 | 0.82 | SLC6A3 (0.40) | ACHEMEN1KMT2AMAPT | |
| SCHEMBL17602006 | 0.82 | ACHE (0.54) | ACHEMEN1RAB9AKMT2AABCB1 | |
| SCHEMBL17601998 | 0.80 | MAPT (0.40) | ACHEMEN1KMT2AMAPTABCB1 | |
| SCHEMBL16002519 | 0.76 | ANPEP (0.43) | ACHEANPEPDPP4 | |
| SCHEMBL17601981 | 0.75 | ADRA2A (0.40) | ACHEHTR2A | |
| SCHEMBL15993833 | 0.75 | CHRNA7 (0.47) | ACHERAB9AHPGDHTTABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160083364-A1 | Phenanthridine Derivatives, Preparation Methods and Uses Thereof | CENTER FOR EXCELLENCE IN MOLECULAR CELL SCIENCE, CHINESE ACADEMY OF SCIENCES (CN) | 2016-03-24 | — | — | US | claimed |
| US-9682954-B2 | Phenanthridine derivatives, preparation methods and uses thereof | KUNMING INSTITUTE OF BOTANY, THE CHINESE ACADEMY OF SCIENCES (CN) | 2017-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160083364-A1 | Phenanthridine Derivatives, Preparation Methods and Uses Thereof | CTNNB1, WNT3A, WNT1 | ALOX15 2340/4885ACHE 3841/4885MEN1 2930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.